Taponeco F, Curcio C, Giuntini A, Nardini V, Fornaciari G, Artini P G, D'Ambrogio G, Genazzani A R
Dept. of Reproductive Medicine and Child Development, University of Pisa, Italy.
J Exp Clin Cancer Res. 2001 Jun;20(2):239-46.
Proteolytic enzymes, like urokinase (uPA) and plasminogen activator inhibitor type-1 (PAI-1), are involved in remodelling tissues during invasion and metastasis of tumor cells. The purpose of the study is to evaluate the expression and the prognostic significance of these enzymes in endometrial hyperplasia and cancer. We used immunohistochemical staining to localize uPA and PAI-1 antigens and evaluate their expression, and the enzyme-linked immunosorbent assay (ELISA) to measure their levels during the progression of endometrial carcinoma. The results show that the levels of uPA and PAI-1 detection are systematically weak in simplex hyperplasia and are moderate in complex hyperplasia. In the endometrial carcinoma a very strong reaction was observed in the most aggressive variant of epithelial tumors. A positive signal for uPA was found only in the cytoplasm of normal and hyperplastic cells while, in tumors, uPA was present also in the cellular areas surrounding the neoplastic glands and at the apex of the malignant cells. The PAI-1 immunoreactivity was weak to moderate in 95.4% of carcinomas, with a diffuse signal mostly distributed in the cytoplasm of neoplastic cells and tumor stroma. UPA antigen concentrations were significantly higher in endometrial carcinoma than in endometrial hyperplasia (p<0.05) and in normal endometrium (p<0.001). PAI-1 antigen concentrations in carcinoma samples were significantly higher than in normal endometrium (p=0.002), but the difference was not statistically significant with respect to that in endometrial hyperplasia. We did not find any correlation between uPA and PAI-1 concentrations and the standard prognostic parameters for evaluating endometrial carcinoma. In conclusion, this study demonstrates that in hyperplastic endometria and in endometrial carcinoma there is a progressive increase in expression of uPA and PAI-1 than in normal endometrial tissue. In carcinoma tissues, the high expression of uPA is unregulated in the surrounding stroma tissue, particularly in the most aggressive histopathologic variants. UPA and PAI-1 may be factors associated with invasive behavior in endometrial carcinoma independent of other clinicopathological parameters.
蛋白水解酶,如尿激酶(uPA)和1型纤溶酶原激活物抑制剂(PAI-1),参与肿瘤细胞侵袭和转移过程中的组织重塑。本研究的目的是评估这些酶在子宫内膜增生和癌症中的表达及预后意义。我们采用免疫组织化学染色定位uPA和PAI-1抗原并评估其表达,采用酶联免疫吸附测定(ELISA)检测子宫内膜癌进展过程中它们的水平。结果显示,单纯性增生中uPA和PAI-1的检测水平系统性较弱,复杂性增生中为中等水平。在子宫内膜癌中,在最具侵袭性的上皮性肿瘤变体中观察到非常强烈的反应。仅在正常和增生细胞的细胞质中发现uPA的阳性信号,而在肿瘤中,uPA也存在于肿瘤腺体周围的细胞区域以及恶性细胞的顶端。95.4%的癌组织中PAI-1免疫反应性为弱阳性至中等强度,弥漫信号主要分布在肿瘤细胞和肿瘤间质的细胞质中。子宫内膜癌中UPA抗原浓度显著高于子宫内膜增生(p<0.05)和正常子宫内膜(p<0.001)。癌组织样本中PAI-1抗原浓度显著高于正常子宫内膜(p=0.002),但与子宫内膜增生相比差异无统计学意义。我们未发现uPA和PAI-1浓度与评估子宫内膜癌的标准预后参数之间存在任何相关性。总之,本研究表明,与正常子宫内膜组织相比,增生性子宫内膜和子宫内膜癌中uPA和PAI-1的表达呈逐渐增加。在癌组织中,uPA在周围间质组织中的高表达不受调控,尤其是在最具侵袭性的组织病理学变体中。UPA和PAI-1可能是与子宫内膜癌侵袭行为相关的因素,独立于其他临床病理参数。